Antipsychotic-induced extrapyramidal symptoms. Role of anticholinergic drugs in treatment

CNS Drugs

Volumn 6, Issue 4, 1996, Pages 315-330

  Barnes, Thomas R E ^a   McPhillips, Mike A ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPERIDEN; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DIAZEPAM; GLYCOPYRRONIUM BROMIDE; LEVODOPA; NEUROLEPTIC AGENT; ORPHENADRINE; PROCYCLIDINE; PROPRANOLOL; TRIHEXYPHENIDYL;

AKATHISIA; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; HUMAN; PARKINSONISM; PRIORITY JOURNAL; REVIEW; TARDIVE DYSKINESIA;

EID: 0029852632     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199606040-00006     Document Type: Review

References (99)

1. Barnes TRE. Movement disorder associated with antipsychotic drugs: the tardive syndromes. Int Rev Psychiatry 1990; 2: 355-66
2. 2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995; 15 Suppl. 1: S57-63
3. Bonner TI. The molecular basis of muscarinic receptor diversity. Trends Neurosci 1989; 12: 148-51
4. Eglen RM, Reddy H, Watson N. Selective inactivation in muscarinic receptor subtypes. Int J Biochemistry 1994; 26 (12): 1357-68
5. Tune L, Coyle JT. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 1982; 139: 1460-2
6. Modell JG, Tandon R, Beresford TP. Dopaminergic activity of the antimuscarinic antiparkinsonian agents. J Clin Psychopharmacol 1989; 9: 347-51
7. Chouinard G, Annable L, Ross-Chouinard A, et al. A five year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988; 8: 21S-6S
8. Gerlach J, Casey DE. Tardive dyskinesia. Acta Psychiatr Scand 1988; 77: 369-78
9. Singh MM, Kay SR. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Psychopharmacologia 1975; 43: 103-13
10. Crow, TJ, Frith CD, Johnson EC, et al. The influence of anticholinergic medication on the extrapyramidal and anti-psychotic effects of neuroleptic drugs in the treatment of acute schizophrenia. Biol Psychiatry 1981; 16: 790-2
11. Johnstone E, Crow T, Ferner N, et al. Adverse effects of anti-cholinergic medication on positive schizophrenic symptoms. Psychol Med 1983; 13: 513-27
12. Woody GE, O'Brien CP. Anticholinergic toxic psychosis in drug abusers treated with benztropine. Compr Psychiatry 1974; 15: 439-42
13. MacVicar K. Abuse of antiparkinson drugs by psychiatric patients. Am J Psychiatry 1977; 134: 809-11
14. Smith JM. Abuse of the antiparkinson drugs: a review of the literature. J Clin Psychiatry 1980; 41: 351-4
15. Crawshaw JA, Mullen PE. A study of benzhexol abuse. Br J Psychiatry 1984; 145: 300-3
16. Aguilera L, Martinez-Bourio R, Cid C, et al. Anaphylactic reaction after atropine. Anaesthesia 1988; 43: 955-7
17. Gardos G, Cole JO, Tarsy D. Withdrawal syndrome associated with antipsycholic drugs. Am J Psychiatry 1978; 135: 1321-4
18. Jellinek T, Gardos G, Cole JO. Adverse effects of antiparkinson drug withdrawal. Arch Gen Psychiatry 1981; 35: 483-9
19. Chouinard G, Bradwejn J, Annable L, et al. Withdrawal symptoms after long-term treatment with low-potency neuroleptic drugs. J Clin Psychiatry 1984; 45: 500-2
20. George V, Castot A, Bidault I. Existe-t-il un syndrome de sevrage specifique aux antiparkinsoniens dopaminergiques? Therapie 1987; 42: 339-41
21. Bermanzohn PC, Siris SG. Noncompliance with antiparkinsonian medications in neuroleptic-treated schizophrenic patients: three cases of an unreported phenomenon. J Clin Psychiatry 1994; 55: 488-91
22. Drachman DA. Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 1977; 27 (8): 783-90
23. Kopelman MD, Corn TH. Cholinergic 'blockade' as a model for cholinergic depletion: a comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakov syndrome. Brain 1988; 111 Pt 5: 1079-110
24. Hitri A, Craft RB, Fallon J, et al. Serum neuroleptic and anticholinergic activity in relation to cognitive toxicity of antiparkinsonian agents in schizophrenic patients. Psychopharmacol Bull 1987; 23: 33-7
25. Baker LA, Cheng LY, Amara IB. The withdrawal of benztropine mesylate in chronic schizophrenic patients. Br J Psychiatry 1983; 143: 584-90
26. Pullen GP, Best NR, MacGuire J. Anticholinergic drug abuse: a common problem? BMJ 1984; 289: 612-3
27. Wells BG, Marken PA, Rickman LA, et al. Characterizing anti-cholinergic abuse in the community. J Clin Psychopharmacol 1989; 9: 431-5
28. Leipzig RA, Mendelowitz A. Adverse psychotropic drug-drug interactions. In: Kane JM, Lieberman JA, editors. Adverse effects of psychotropic drugs. New York: The Guilford Press, 1992: 13-76
29. Tonda ME, Guthrie SK. Treatment of neuroleptic-induced movement disorders. Pharmacotherapy 1994; 14: 543-60
30. Leon JD, Simpson GM. Assessment of neuroleptic-induced extrapyramidal symptoms. In: Kane JM, Lieberman JA, editors. Adverse effects of psychotropic drugs. New York: The Guilford Press, 1992: 218-34
31. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992; 9: 538-44
32. Lavin MR, Rifkin A. Prophylactic antiparkinson drug use: I. Initial prophylaxis and prevention of side effects. J Clin Pharmacol 1991; 31: 763-8
33. Ebel H. Therapy of neuroleptic-induced extrapyramidal movement disorders. Neurol Psychiatry Brain Res 1994; 2: 140-51
34. Lake CR, Casey DE, McEvoy JP, et al. The 'pros' and 'cons' of anticholinergic prophylaxis. Psychopharmacol Bull 1986; 22: 981-4
35. Winslow RS, Stiller V, Coons DJ, et al. Prevention of acute dystonic reactions in patients beginning high-potency neuroleptics. Am J Psychiatry 1986; 143: 706-10
36. Boyer WF, Bakalar NH, Lake CR. Anticholinergic prophylaxis ol acute haloperidol-induced acute dystonic reactions. J Clin Psychopharmacol 1987; 7: 164-6
37. Keepers GA, Casey DH. Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol 1987; 7: 342-5
38. Arana GW, Goff DC, Baldessarini RJ, et al. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 1988; 145: 993-6
39. Goff DC, Arana GW, Greenblatt DJ, et al. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol 1991; 11: 106-12
40. Manos N, Lavrentiadis G, Ckiouzepas J. Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics. J Clin Psychiatry 1986; 47: 114-6
41. Rifkin A, Quitkin F, Kane JM, et al. Are prophylactic antiparkinson drugs necessary? Arch Gen Psychiatry 1978; 35: 483-9
42. World Health Organization, Heads of centres collaborating in WHO co-ordinated studies on biological aspects of mental illness. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment: a consensus statement. Br J Psychiatry 1990; 156: 412
43. McClelland HA, Blessed G, Bhate S, et al. The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients. Br J Psychiatry 1974; 124: 151-9
44. Orlov P, Kasparian G, Dimascio A, et al. Withdrawal of antiparkinson drugs. Arch Gen Psychiatry 1971; 25: 410-2
45. Simpson GM, Angus JWS. A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand 1970; 212: 11-9
46. Raleigh FR. Reducing unnecessary antiparkinson medication in antipsychotic drug therapy. J Am Pharm Assoc 1977; NS17: 101-2
47. Johnson DAW. Prevalence and treatment of drug-induced extrapyramidal symptoms. Br J Psychiatry 1978; 132: 27-30
48. Silver H, Geraisy N, Schwartz M. No differences in the effect of biperiden and amantadine on parkinsonian and tardive dyskinesia-type involuntary movements: a double-blind cross-over placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 1995; 56: 167-70
49. Mindham RHS. Assessment of drug-induced extrapyramidal reactions and of drugs given for their control. Br J Clin Pharmacol 1976; Suppl.: 395-400
50. Comaty JE, Janicak MD, Rajaratnam J, et al. Is maintenance antiparkinsonian treatment necessary? Psychopharmacol Bull 1990; 26: 267-70
51. Manos N, Gkiouzepas J, Logothetis J. The need for continuous use of antiparkinson medication with chronic schizophrenic patients receiving long-term neuroleptic therapy. Am J Psychiatry 1981; 138: 184-8
52. Klett CJ, Point P, Caffey E. Evaluating the long-term need for antiparkinsonian drugs by chronic schizophrenics. Arch Gen Psychiatry 1972; 26: 375-9
53. Leegood H, Barnes TRE, Liddle PF. The effects of abrupt procyclidine withdrawal in a chronic schizophrenic inpatient population - a double-blind study [abstract]. Psychiatr Bull 1991; 15 Suppl. 4: 92
54. Barnes TRE. Comment on the WHO consensus statement. Br J Psychiatry 1990; 156: 413-4
55. Van Putten T, May PRA. 'Akinetic depression' in schizophrenia. Arch Gen Psychiatry 1978; 35: 1101-7
56. Barnes TRE, McPhillips MA. How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 115-21
57. Siris SG. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. Br J Psychiatry 1993; 163 Suppl. 22: 66-78
58. Hogarty GE, McEvoy JP, Ulrich RF, et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry 1995; 52: 29-41
59. Kane JM, Woerner M, Sarantakos S. Depot neuroleptics: a comparative review of standard, intermediate and low-dose regimens. J Clin Psychiatry 1986; 47 Suppl.: 30-4
60. Swett CJ. Drug-induced dystonia. Am J Psychiatry 1975; 132: 532-4
61. Burke RE. Neuromuscular effects of neuroleptics: dystonia. In: Kane JM, Lieberman JA, editors. Adverse effects of psychotropic drugs. New York: Guilford Press, 1992: 189-200
62. Angus JWS, Simpson GM. Hysteria and drug-induced dystonia. Acta Psychiatr Scand 1970; 212: 52-8
63. Rupniak NMJ, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. Psychopharmacology 1986; 103: 138-9
64. Addonzio G, Alexopolous GS. Drug-induced dystonia in young and elderly patients. Am J Psychiatry 1988; 145: 869-71
65. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054-60
66. Stern TA, Anderson WH. Benztropine prophylaxis of dystonic reactions. Psychopharmacology 1979; 61: 261-2
67. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No. 31. London: British Medical Association and The Pharmaceutical Press, 1996 Mar
68. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsycholic drugs. Neurology 1982; 32: 1335-46
69. Sachdev P. Risk factors for tardive dystonia: a case control comparison with tardive dyskinesia. Acta Psychiatr Scand 1993; 88: 98-103
70. Friedman JH, Kuraski LT, Wagner RI. Tardive dystonia in a psychiatric hospital. J Neurol Neurosurg Psychiatry 1987; 50: 801-3
71. Yassa R, Nair V, Dimitry R. Prevalence of tardive dystonia. Acta Psychiatr Scand 1986; 73: 629-33
72. Marsden CD, Quinn NP. The dystonias. BMJ 1990; 300: 139-44
73. Jankovic J, Schwartz K. Botulinum toxin injection for cervical dystonia. Neurology 1990; 40: 277-80
74. Anderson TJ, Rivest J, Stell R, et al. Botulinum toxin treatment of spasmodic torticollis. J R Soc Med 1992; 85: 525-9
75. Safferman A, Lieberman JA, Kane JM, et al. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991; 17: 247-61
76. Friedman JH. Clozapine treatment of psychosis in patients with tardive dystonia. Mov Disord 1994; 9: 321-4
77. Barnes TRE. Neuromuscular effects of neuroleptics: akathisia. In: Kane JM, Lieberman JA, editors. Adverse effects of psychotropic drugs. New York: Guilford Press, 1992: 201-17
78. Braude WM, Barnes TRE, Gore SM. Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 1983; 143: 139-50
79. Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 1994; 51: 963-74
80. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31: 67-72
81. Van Putten T, Marder S. Behavioural toxicity of antipsychotic drugs. J Clin Psychiatry 1987; 48: 13-9
82. Ayd FJ. Akathisia and suicide: fact or myth? Int Drug Ther News Lett 1988; 23: 37-8
83. Wilbur R, Kulik AV. Propranolol for akathisia [letter]. Lancet 1983; II: 917
84. Lipinski JF, Zubenko OS, Cohen BN, et al. Propranolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1983; 141: 412-5
85. Adler L, Angrist B, Peselow E, et al. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 1986; 149: 42-5
86. Friis T, Christensen TR, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. Acta Psychiatr Scand 1983; 67: 178-87
87. Kruse W. Persistent muscular restlessness after phenothiazine treatment: a report of three cases. Am J Psychiatry 1960; 17: 152-3
88. Marsden CD, Tarsy D, Baldessarini RJ. Spontaneous and drug-induced movement disorders in psychiatric patients. In: Benson DF, Blumer D, editors. Psychiatric aspects of neurological disease. New York: Grune and Stratton, 1975: 219-65
89. Sovner R, DiMascio A. Extrapyramidal syndromes and other neurological side-effects of psychotropic drugs. In: Lipton MA, Di Mascio A, Killam KF, editors. Psychopharmacology: a generation of progress. New York: Raven Press, 1978: 1021-32
90. Weiner WJ, Luby ED. Persistent akathisia following neuroleptic withdrawal. Ann Neurol 1983; 13: 466-7
91. Barnes TRE, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985; 42: 874-8
92. Gibb WRG, Lees AJ. The clinical phenomenon of akathisia. J Neurol Neurosurg Psychiatry 1986; 49: 861-6
93. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors 1959-1979. Arch Gen Psychiatry 1982; 39: 473-81
94. Wada Y, Yamaguchi N. The rabbit syndrome and antiparkinsonian medication in schizophrenic patients. Neuropsychobiology 1992; 25: 149-52
95. Yassa R, Lal S. Prevalence of the rabbit syndrome. Am J Psychiatry 1986; 143: 656-7
96. Gardos G, Cole JO. Tardive dyskinesia and anticholinergic drugs. Am J Psychiatry 1983; 140: 200-2
97. Kane JM, Woerner M, Borenstein M. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986; 22: 254-8
98. Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266: 2402-6
99. Kane JM, Jeste DV, Barnes TRE, et al. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1992